Menu Search
Equities

China Isotope & Radiation Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
1763:HKG.HS

China Isotope & Radiation Corp

Actions
  • Price (HKD)20.50
  • Today's Change-0.10 / -0.49%
  • Shares traded15.00k
  • 1 Year change+80.46%
  • Beta0.8245
Data delayed at least 15 minutes, as of Feb 16 2026 02:34 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

China Isotope & Radiation Corp is a China-based company mainly engaged in the research, development, manufacturing and sale of diagnostic and therapeutic radiopharmaceuticals and radioactive source products. The Company operates five business segments. Pharmaceuticals segment is engaged in providing imaging diagnostic and therapeutic radiopharmaceuticals, urea breath test (UBT) kits and analyzers and in vitro diagnostic reagents and kits. Radioactive Source Products segment is engaged in providing various medical and industrial radioactive sources products as well as provision of related technical services. Irradiation segment is engaged in providing sterilization services. Radiation Therapy Equipment and Related Services segment is engaged in manufacturing Radiation therapy equipment. Other Businesses segment is engaged in providing trade services in relation to imported radioactive source, medical nuclides, imported radiopharmaceuticals, and other products.

  • Revenue in HKD (TTM)8.62bn
  • Net income in HKD479.84m
  • Incorporated1983
  • Employees3.36k
  • Location
    China Isotope & Radiation CorpNo. 66 Changwa Middle StreetHaidian DistrictBEIJING ChinaCHN
  • Phone+86 1 068411265
  • Fax+86 1 068512374
  • Websitehttp://www.china-isotope.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.